Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Authors:

Abstract
No abstract available
Funding Information
  • Janssen Research and Development

This publication has 17 references indexed in Scilit: